These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
194 related items for PubMed ID: 30761939
21. Sexual function and the use of medical devices or drugs to optimize potency after prostate brachytherapy. Whaley JT, Levy LB, Swanson DA, Pugh TJ, Kudchadker RJ, Bruno TL, Frank SJ. Int J Radiat Oncol Biol Phys; 2012 Apr 01; 82(5):e765-71. PubMed ID: 22300559 [Abstract] [Full Text] [Related]
22. Effect of aging and long-term erectile function after iodine-125 prostate brachytherapy. Keyes M, Pickles T, Crook J, McKenzie M, Cheung A, Spadinger I, LaPointe V, Bachand WF, Morris J. Brachytherapy; 2015 Apr 01; 14(3):334-41. PubMed ID: 25684438 [Abstract] [Full Text] [Related]
23. [Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: The Hotel-Dieu of Quebec experience]. Zebentout O, Apardian R, Beaulieu L, Harel F, Martin AG, Vigneault E. Cancer Radiother; 2010 Jun 01; 14(3):183-8. PubMed ID: 20418145 [Abstract] [Full Text] [Related]
24. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. Lawton CA, Yan Y, Lee WR, Gillin M, Firat S, Baikadi M, Crook J, Kuettel M, Morton G, Sandler H. Int J Radiat Oncol Biol Phys; 2012 Apr 01; 82(5):e795-801. PubMed ID: 22330999 [Abstract] [Full Text] [Related]
25. Dose-volume parameters of the corpora cavernosa do not correlate with erectile dysfunction after external beam radiotherapy for prostate cancer: results from a dose-escalation trial. van der Wielen GJ, Hoogeman MS, Dohle GR, van Putten WL, Incrocci L. Int J Radiat Oncol Biol Phys; 2008 Jul 01; 71(3):795-800. PubMed ID: 18164862 [Abstract] [Full Text] [Related]
26. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Stock RG, Stone NN, DeWyngaert JK, Lavagnini P, Unger PD. Cancer; 1996 Jun 01; 77(11):2386-92. PubMed ID: 8635111 [Abstract] [Full Text] [Related]
27. An age-corrected matched-pair study of erectile function in patients treated with dose-escalated adaptive image-guided intensity-modulated radiation therapy vs. high-dose-rate brachytherapy for prostate cancer. Marina O, Warner J, Ye H, Grills IS, Shah C, Wallace M, Gustafson GS, Brabbins DS, Martinez AA, Krauss DJ. Brachytherapy; 2014 Jun 01; 13(2):163-8. PubMed ID: 24295963 [Abstract] [Full Text] [Related]
28. Association between long-term erectile dysfunction and biochemical recurrence after permanent seed I(125) implant brachytherapy for prostate cancer. A longitudinal study of a single-institution. Morgia G, Castelli T, Privitera S, Al-Nakib C, Favilla V, Marchese F, Cimino S, Russo GI. Aging Male; 2016 Jun 01; 19(1):15-9. PubMed ID: 26376010 [Abstract] [Full Text] [Related]
29. Permanent prostate brachytherapy-induced morbidity in patients with grade II and III obesity. Merrick GS, Butler WM, Wallner K, Galbreath RW, Anderson RL, Kurko BS, Lief JH. Urology; 2002 Jul 01; 60(1):104-8. PubMed ID: 12100933 [Abstract] [Full Text] [Related]
30. Temporal patterns of selected late toxicities in patients treated with brachytherapy or brachytherapy plus external beam radiation for prostate adenocarcinoma. Buckstein M, Kerns S, Forysthe K, Stone NN, Stock RG. BJU Int; 2013 Mar 01; 111(3 Pt B):E43-7. PubMed ID: 23046084 [Abstract] [Full Text] [Related]
31. Factors predicting an increased dose to the penile bulb in permanent seed prostate brachytherapy. Taussky D, Haider M, McLean M, Yeung I, Williams T, Pearson S, Lockwood G, Crook J. Brachytherapy; 2004 Mar 01; 3(3):125-9. PubMed ID: 15533803 [Abstract] [Full Text] [Related]
32. Reduced radiation tolerance of penile structures associated with dose-escalated hypofractionated prostate radiotherapy. McDonald AM, Baker CB, Shekar K, Popple RA, Clark GM, Yang ES, Jacob R, Kim RY, Fiveash JB. Urology; 2014 Dec 01; 84(6):1383-7. PubMed ID: 25440987 [Abstract] [Full Text] [Related]
33. Potency after permanent prostate brachytherapy for localized prostate cancer. Potters L, Torre T, Fearn PA, Leibel SA, Kattan MW. Int J Radiat Oncol Biol Phys; 2001 Aug 01; 50(5):1235-42. PubMed ID: 11483334 [Abstract] [Full Text] [Related]
34. Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: Association between dose and late toxicity. Rose JN, Crook JM, Pickles T, Keyes M, Morris WJ. Brachytherapy; 2015 Aug 01; 14(3):342-9. PubMed ID: 25727178 [Abstract] [Full Text] [Related]
35. Proposal for a predictive model of erectile function after permanent (125)I prostate brachytherapy for localized prostate cancer. Huyghe E, Delaunay B, Njomnang Soh P, Delannes M, Walschaerts M, Delavierre D, Soulie M, Bachaud JM. Int J Impot Res; 2013 Aug 01; 25(4):121-6. PubMed ID: 23446806 [Abstract] [Full Text] [Related]
38. Favorable preservation of erectile function after prostate brachytherapy for localized prostate cancer. Bazinet A, Zorn KC, Taussky D, Delouya G, Liberman D. Brachytherapy; 2020 Aug 01; 19(2):222-227. PubMed ID: 31837989 [Abstract] [Full Text] [Related]